JP2024170466A5 - - Google Patents

Download PDF

Info

Publication number
JP2024170466A5
JP2024170466A5 JP2024147372A JP2024147372A JP2024170466A5 JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5 JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
use according
inhibitor
additional anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024147372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024170466A (ja
JP7793001B2 (ja
Filing date
Publication date
Priority claimed from JP2022535120A external-priority patent/JP7606518B2/ja
Application filed filed Critical
Publication of JP2024170466A publication Critical patent/JP2024170466A/ja
Publication of JP2024170466A5 publication Critical patent/JP2024170466A5/ja
Priority to JP2025154024A priority Critical patent/JP2025178337A/ja
Priority to JP2025154025A priority patent/JP2025178338A/ja
Application granted granted Critical
Publication of JP7793001B2 publication Critical patent/JP7793001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024147372A 2020-01-06 2024-08-29 抗ccr8抗体及びその使用 Active JP7793001B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025154024A JP2025178337A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用
JP2025154025A JP2025178338A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062957758P 2020-01-06 2020-01-06
US62/957,758 2020-01-06
US202062985152P 2020-03-04 2020-03-04
US62/985,152 2020-03-04
US202063198803P 2020-11-13 2020-11-13
US63/198,803 2020-11-13
JP2022535120A JP7606518B2 (ja) 2020-01-06 2021-01-06 抗ccr8抗体及びその使用
PCT/US2021/012329 WO2021142002A1 (en) 2020-01-06 2021-01-06 Anti-ccr8 antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022535120A Division JP7606518B2 (ja) 2020-01-06 2021-01-06 抗ccr8抗体及びその使用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025154024A Division JP2025178337A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用
JP2025154025A Division JP2025178338A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2024170466A JP2024170466A (ja) 2024-12-10
JP2024170466A5 true JP2024170466A5 (cg-RX-API-DMAC10.html) 2025-02-12
JP7793001B2 JP7793001B2 (ja) 2025-12-26

Family

ID=74418541

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022535120A Active JP7606518B2 (ja) 2020-01-06 2021-01-06 抗ccr8抗体及びその使用
JP2024147372A Active JP7793001B2 (ja) 2020-01-06 2024-08-29 抗ccr8抗体及びその使用
JP2025154025A Pending JP2025178338A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用
JP2025154024A Pending JP2025178337A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022535120A Active JP7606518B2 (ja) 2020-01-06 2021-01-06 抗ccr8抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025154025A Pending JP2025178338A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用
JP2025154024A Pending JP2025178337A (ja) 2020-01-06 2025-09-17 抗ccr8抗体及びその使用

Country Status (12)

Country Link
US (3) US11859000B2 (cg-RX-API-DMAC10.html)
EP (1) EP4087607A1 (cg-RX-API-DMAC10.html)
JP (4) JP7606518B2 (cg-RX-API-DMAC10.html)
KR (2) KR102821932B1 (cg-RX-API-DMAC10.html)
CN (1) CN114929278A (cg-RX-API-DMAC10.html)
AR (1) AR132614A2 (cg-RX-API-DMAC10.html)
AU (2) AU2021205877B2 (cg-RX-API-DMAC10.html)
CA (1) CA3160204A1 (cg-RX-API-DMAC10.html)
IL (2) IL294330B2 (cg-RX-API-DMAC10.html)
MX (3) MX2022008341A (cg-RX-API-DMAC10.html)
TW (2) TWI906906B (cg-RX-API-DMAC10.html)
WO (1) WO2021142002A1 (cg-RX-API-DMAC10.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3431105T (pt) * 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
WO2021155097A1 (en) * 2020-01-29 2021-08-05 The Wistar Institute Of Anatomy And Biology Cd40-l blockade to enhance synthetic antibody therapy
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
WO2022211046A1 (ja) 2021-03-31 2022-10-06 塩野義製薬株式会社 Ccr8を抗原として認識するキメラ抗原受容体
AU2022285741A1 (en) 2021-06-04 2023-12-14 Amgen Inc. Anti-ccr8 antibodies and uses thereof
TWI920354B (zh) * 2021-07-27 2026-04-01 美商艾伯維有限公司 抗ccr8抗體
JP2024531409A (ja) * 2021-08-20 2024-08-29 ハイファイバイオ, インコーポレイテッド 抗ccr8抗体およびその使用
CN119930823A (zh) * 2021-12-23 2025-05-06 乐普创一生物科技(上海)有限公司 抗ccr8抗体及其应用
EP4463484A4 (en) * 2022-01-14 2026-02-25 Qilu Puget Sound Biotherapeutics Corp Anti-ccr8 antibodies
CN116789820A (zh) * 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
WO2023206350A1 (en) * 2022-04-29 2023-11-02 Analytical Biosciences Shanghai Limited Anti-ccr8 antibodies and uses thereof
CN119948055A (zh) 2022-05-24 2025-05-06 百时美施贵宝公司 结合人ccr8的抗体
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
EP4552647A4 (en) * 2022-07-07 2026-06-17 Sichuan Swiftbio Biotechnology Co Ltd CCR8 ANTIBODIES AND THEIR USES
AU2023319869A1 (en) * 2022-08-04 2025-02-20 Beone Medicines I Gmbh Anti-ccr8 antibodies and methods of use
CA3265264A1 (en) * 2022-08-19 2024-02-22 Fibrogen, Inc. CCR8 ANTIBODIES AND THEIR USES
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
US20260234276A1 (en) 2022-09-21 2026-08-13 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024094003A1 (zh) * 2022-11-04 2024-05-10 普米斯生物技术(珠海)有限公司 抗ccr8的抗体及其用途
CN120239710A (zh) * 2022-11-22 2025-07-01 上海宏成药业有限公司 抗ccr8抗体及其用途
TW202423987A (zh) * 2022-12-07 2024-06-16 大陸商廣東菲鵬製藥股份有限公司 抗ccr8抗體及其應用
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
TW202511293A (zh) * 2023-05-23 2025-03-16 中國大陸商再鼎醫藥(上海)有限公司 包含抗ccr8抗體的製劑及其用途
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
EP4727974A1 (en) * 2023-06-16 2026-04-22 Genor Biopharma Co., Ltd. Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
CN117285627B (zh) * 2023-09-06 2024-06-14 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
CN122341642A (zh) 2023-09-21 2026-07-03 多曼治疗学公司 抗ccr8单克隆抗体及其治疗用途
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026017820A1 (en) * 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (en) * 2024-07-18 2026-01-21 Egle Therapeutics Immunocytokine for cancer treatment
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
US12673112B2 (en) * 2024-12-09 2026-07-07 Takeda Pharmaceutical Company Limited CCR8 antibodies, antibody conjugates, and uses thereof
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
WO2018112032A1 (en) * 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
PT3431105T (pt) * 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
WO2019157098A1 (en) * 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
AU2021205877B2 (en) * 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
IL321341A (en) Anti-CCR8 antibodies and their uses
JP2023509323A5 (cg-RX-API-DMAC10.html)
JP7608164B2 (ja) 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
Gan et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy
JP7137474B2 (ja) NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
TWI908743B (zh) 抗dll3藥劑之給藥方案
JP2018525354A5 (cg-RX-API-DMAC10.html)
TW201834697A (zh) Her2標靶抗體-藥物結合物之組合療法
CN118078987A (zh) 抗folr1免疫缀合物与抗pd-1抗体的组合
CN112218662A (zh) 抗cd37免疫缀合物给药方案
US12234293B2 (en) Treatment for primary amyloidosis with anti-BCMA binding protein
JP2019023227A (ja) 神経障害及び疼痛のegfr標的治療
TW202116810A (zh) 用於治療癌症之人化抗liv1抗體
EP3691682A1 (en) Combination treatment for cancer
IL322208A (en) Methods and preparations for combined therapy
He et al. Discovery of a novel EGFR-targeting antibody–drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies
CN116712539A (zh) 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途
TW202306588A (zh) 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途
TW202508637A (zh) 修飾的抗體、其抗體片段和抗體藥物偶聯物
KR102529267B1 (ko) 이중 특이성 항체를 이용한 항체 약물 복합체 플랫폼
AU2022331610A1 (en) Interleukin-12 variants and methods of use
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
CN110177807B (zh) 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗
CN119894929A (zh) 使用PD-1或PD-L1抑制剂和靶向Claudin 18.2的抗体药物偶联物的癌症治疗
JP2025508739A5 (cg-RX-API-DMAC10.html)